Novel oral anticoagulants. Part II: Direct thrombin inhibitors

  • Mehta R
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The quest for an ideal anticoagulant is ongoing. Oral agents that do not require blood level monitoring are presently undergoing taut scrutiny for efficacies and potential side effects, and could soon be ready to transform the history of coagulation medicine. The first part of this article (published in last months Expert Review of Hematology) embraced a comprehensive review of oral Factor Xa inhibitors, such as rivaroxaban, apixaban, eribaxaban, edoxaban, YM150. This second part of the article reviews novel oral direct thrombin inhibitors, such as dabigatran and AZD0837, and a brief description of oral Factor IXa inhibitors, such as TTP889. © 2010 Expert Reviews Ltd.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Rohtesh S. Mehta

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free